These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18309145)

  • 1. A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke.
    Savitz SI; Schäbitz WR
    Stroke; 2008 Apr; 39(4):1389-91. PubMed ID: 18309145
    [No Abstract]   [Full Text] [Related]  

  • 2. Stroke: the dashed hopes of neuroprotection.
    Hill MD
    Lancet Neurol; 2007 Jan; 6(1):2-3. PubMed ID: 17166787
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroprotection in the SAINT-II aftermath.
    Hermann DM; Bassetti CL
    Ann Neurol; 2007 Dec; 62(6):677-8; author reply 678. PubMed ID: 17849454
    [No Abstract]   [Full Text] [Related]  

  • 4. SAINT-I worked, but the neuroprotectant is not NXY-059.
    Proctor PH; Tamborello LP
    Stroke; 2007 Oct; 38(10):e109; author reply e110. PubMed ID: 17717310
    [No Abstract]   [Full Text] [Related]  

  • 5. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke.
    Koziol JA; Feng AC
    Stroke; 2006 Oct; 37(10):2644-7. PubMed ID: 16946150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life after SAINT.
    Hallevi H; Aronowski J
    Int J Stroke; 2007 Nov; 2(4):241-2. PubMed ID: 18705923
    [No Abstract]   [Full Text] [Related]  

  • 7. [Development of new stroke therapies: outlook for neuroprotective drugs].
    Rogalewski A; Schäbitz WR
    Nervenarzt; 2008 Feb; 79(2):218-24. PubMed ID: 18214414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection failure in stroke.
    Drummond JC; Piyash PM; Kimbro JR
    Lancet; 2000 Sep; 356(9234):1032-3. PubMed ID: 11041427
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel approaches to neuroprotection trials in acute ischemic stroke.
    Tymianski M
    Stroke; 2013 Oct; 44(10):2942-50. PubMed ID: 24021680
    [No Abstract]   [Full Text] [Related]  

  • 10. NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized?
    Fisher M
    Stroke; 2006 Oct; 37(10):2651-2. PubMed ID: 16946143
    [No Abstract]   [Full Text] [Related]  

  • 11. NXY-059: review of neuroprotective potential for acute stroke.
    Fong JJ; Rhoney DH
    Ann Pharmacother; 2006 Mar; 40(3):461-71. PubMed ID: 16507608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials.
    Savitz SI; Fisher M
    Ann Neurol; 2007 May; 61(5):396-402. PubMed ID: 17420989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.
    Philip M; Benatar M; Fisher M; Savitz SI
    Stroke; 2009 Feb; 40(2):577-81. PubMed ID: 19074479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection in cerebral ischemia: emphasis on the SAINT trial.
    Chacon MR; Jensen MB; Sattin JA; Zivin JA
    Curr Cardiol Rep; 2008 Feb; 10(1):37-42. PubMed ID: 18416999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it time to definitely abandon neuroprotection in acute ischemic stroke?
    Sacchetti ML
    Stroke; 2008 Jun; 39(6):1659-60. PubMed ID: 18369169
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroprotective effects of free radical scavengers in stroke.
    Wang CX; Shuaib A
    Drugs Aging; 2007; 24(7):537-46. PubMed ID: 17658905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?
    Emerich DF
    Trends Neurosci; 2000 Jun; 23(6):245-6. PubMed ID: 10838591
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical impact of NXY-059 demonstrated in the SAINT I trial: derivation of number needed to treat for benefit over entire range of functional disability.
    Saver JL
    Stroke; 2007 May; 38(5):1515-8. PubMed ID: 17395871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues pertaining to the critiques of the SAINT-I Trial.
    Fisher M; Hess DC; Lees K
    Stroke; 2007 Nov; 38(11):e126-7; author reply e128. PubMed ID: 17968005
    [No Abstract]   [Full Text] [Related]  

  • 20. To serve and neuroprotect.
    Dolgin E
    Nat Med; 2012 Jul; 18(7):1003-6. PubMed ID: 22772545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.